These rights will allow ROVI to distribute the product in Spain, in its different pharmaceutical forms, under the trademarks POLARAMINE® and POLARACREM™, and, in its injectable form in France.
Fri, 15/02/2019 - 11:15
2 minThese rights will allow ROVI to distribute the product in Spain, in its different pharmaceutical forms, under the trademarks POLARAMINE® and POLARACREM™, and, in its injectable form in France.
IMG_9783(1).jpg
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has reached an agreement with a subsidiary of MSD (“MSD”) whereby ROVI acquires certain rights to MSD’s dexchlorpheniramine maleate product line in Spain and France, allowing it to distribute this product directly in Spain in its different pharmaceutical forms (tablets, syrup and ampoules, marketed under the brand name POLARAMINE®, and cream, marketed under the brand name POLARACREM™) and, in France, in its injectable form (ampoules).
This line of products belongs to a group of medicines known as antihistamines used for symptomatic treatment of seasonal and perennial allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis; mild, uncomplicated allergic cutaneous manifestations of urticaria or angioedema; and reactions to blood or plasma. They are also indicated, together with adrenalin or other appropriate measures, for treatment of anaphylactic reactions after the acute manifestations have been controlled. These products often relieve cutaneous manifestations such as allergic eczema, atopic and contact dermatitis, insect bites, dermographisms and drug reactions.
According to MSD, net sales of these products in Spain and France, were approximately 6.3 million US dollars in 2017.
ROVI will pay MSD 13.5 million euros for the product.
Under this agreement, this line of products will be marketed directly by ROVI in Spain in its different pharmaceutical forms and, in France, in its injectable form, when the administrative procedures to authorise the transfer of the marketing authorisations have been concluded at the Spanish Medicines Agency and the French Agency for the Safety of Medicines and Health Products.
Juan López-Belmonte Encina, ROVI’s CEO, said: “With these products ROVI strengthens its position in Spain, its main market, and in France, one of the largest markets in Europe, as part of its strategy to become a European player. Likewise, this acquisition fully complements our existing portfolio and will immediately have a favourable impact on the company’s profits”.